argenx reported a strong Q2 driven by increased profitability, robust cash flow, and operational efficiency in its autoimmune drug franchise. Its efgartigimod treatment, especially for generalized myasthenia gravis (gMG), supports a valuation exceeding $50 billion. The company has $3.6 billion in cash, minimal debt, and funds its own R&D, positioning it well for future innovation and pipeline growth, including upcoming clinical catalysts like empasiprubart for MMN. Analysts upgraded argenx to buy, citing accelerating fundamentals and strong cash reserves as justification for its premium valuation.
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
BiomX's subsidiary Zorronet has partnered with Czech company Samura s.r.o. to expand its AI-powered monitoring technology across Central and Eastern Europe. The collaborations focus on smart pest management in agriculture and protecting critical tran...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share transactions on July 23, 2026. The bank purchased 640,099 ordinary shares at prices between 280 and 280.25 per unit and sold 650,000 sh...
West Pharmaceutical Services reported strong 2Q26 results with revenue of $872.3M, up 13.8% year-over-year, and adjusted EPS of $2.37, beating consensus by $0.29. The company raised its full-year guidance to $3.345–$3.380 billion in sales and $8.85–$...
Circle, the issuer of the USDC stablecoin, minted 250 million new USDC tokens, adding to the circulating supply. This minting event is part of Circle's routine process to align token supply with dollar reserves and meet demand. While such large mints...
